Business Wire

IL-FOURKITES

Share
FourKites and Spotos Join Forces to Bring Real-time Supply Chain Visibility to European Shippers

Leading real-time supply chain visibility company FourKites today announced it will bring its network of end-to-end, real-time supply chain data to Spotos’ European customers. German-based Spotos offers a digital freight forwarding platform that gives shippers access to a wide network of carriers across Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005078/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites and Spotos Join Forces to Bring Real-time Supply Chain Visibility to European Shippers (Graphic: Business Wire)

The partnership can give Spotos’ customers up-to-the-minute predictive estimated times of arrival (ETAs) and real-time status updates for their shipments at anytime, anywhere in Europe, whether in transit or at rest. With these advanced insights provided by FourKites, Spotos’ customers can reduce dwell and detention costs while optimising their network as shippers look to manage their costs better.

“Our mission is to revolutionise traditional freight exchange by enabling the best transparency, simplicity and accessibility for small and medium shippers,” said Šarūnas Stanislovėnas, founder and CEO of Spotos. “Now, thanks to FourKites' predictive insights, we will be able to provide our customers with ETAs that are more accurate and detailed than other available technologies could reliably deliver."

Spotos will also leverage FourKites’ carrier visibility platform, NIC-Place. This will give its customers access to granular data, including temperature tracking data for high-value transports, such as pharmaceuticals, fresh and frozen products, and electronic equipment throughout all parts of their fleet. With its proprietary Data Control Center (DCC), FourKites’ NIC-Place solution can provide a flexible and secure way for carriers to share supply chain data with customers, while giving them complete control of their business, their network and their data.

Based in Berlin, Spotos’ fully automated spot freight forwarding platform assures the highest-level service experience for small and medium-sized (SMB) shippers, regardless of their order volume or frequency. FourKites’ offering — powered by cutting-edge artificial intelligence and machine learning — will integrate with Spotos’ platform to extend visibility beyond transportation into yards, warehouses, stores and more.

Visibility across the entire supply chain network is crucial for SMB customers shipping high-value goods. By leveraging FourKites’ market-leading data network, Spotos’ customers can dynamically react to changes in plans and make more informed decisions in real time. In addition, FourKites will fuel insights that drive smarter operational planning and uncover new opportunities for operational efficiencies and cost savings.

“We’re delighted to team up with Spotos to ensure their customers can seamlessly track their freight in one unified platform,” said Marc Boileau, FourKites’ Senior Vice President of Sales, Network & Operations EMEA. “With FourKites, Spotos gets the most advanced tracking features for true end-to-end visibility, giving them a single pane of glass solution and the industry’s most accurate predictive ETAs for every shipment.”

“We’re excited about our partnership with FourKites,” continued Stanislovėnas. “FourKites has proven itself to be a true partner that has our best interests at heart and is always striving to do what’s right for our business and our customers.”

About FourKites

Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

About Spotos

Spotos revolutionised the old-school logistics industry, combining it with cutting-edge innovation, customer-oriented design, and a futuristic vision. It offers shippers access to a wide network of carriers across the EU region. The platform powertrain includes data science, artificial intelligence and machine learning.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005078/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 14:30:00 CET | Press release

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 14:00:00 CET | Press release

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 14:00:00 CET | Press release

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 using a randomized, multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes across three indications: metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in pre-chemotherapy and post-177Lu-PSMA radioligand therapy (RLT) settings AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling

Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 14:00:00 CET | Press release

Establishment of the London office follows Luma AI’s $900 million Series C investment led by HUMAIN - marking the company’s first major step towards international scale with plans to deepen partnerships across the UK, European Union, and Saudi Arabia in the first phase of expansion.Former Monks and WPP executive Jason Day was appointed Head of EMEA to launch Luma AI internationally and drive worldwide growth across creative, advertising, gaming, and entertainment sectors.Luma AI plans to add 200 new jobs in London in 2026. Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING

Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 13:30:00 CET | Press release

Eventbrite stockholders to receive $4.50 per share in cash Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after cl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye